|
End-of-day quote
Euronext Paris
05/02/2024
|
5-day change | 1st Jan Change | ||
| 1.980 EUR | -1.00% |
|
-1.00% | -1.00% |
| 06-30 | Neovacs bolsters its strategic intellectual property portfolio |  |
| 02-10 | Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted | CI |
Company Valuation: NEOVACS
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Enterprise Value (EV) 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| P/E | -96,912,987x | -264,999,452x | -6,728x | -22,860,253x | - | - |
| PBR | - | - | - | - | - | - |
| PEG | - | 3,273,301.5x | -0x | 229,169x | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0479 | -0.009117 | -5.946 | -0.0147 | - | - |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.0952 | 0.031 | 0.0225 | 0.001112 | 0.5334 | 0.4339 |
| EBITDA 1 | -8.118 | -3.437 | -7.728 | -6.294 | -6.06 | -6.43 |
| EBIT 1 | -8.175 | -3.492 | -7.828 | -6.445 | -6.908 | -6.622 |
| Net income 1 | -7.548 | -6.143 | -11.84 | -3.549 | -8.743 | -32.91 |
| Net Debt 1 | -1.234 | -9.681 | -32.06 | -5.555 | -0.2365 | -0.2051 |
| Reference price 2 | 4,640,000.0000 | 2,416,000.0000 | 40,000.0000 | 336,000.0000 | 20,000.0000 | 10,212,000.0000 |
| Nbr of stocks (in thousands) | - | - | - | - | - | - |
| Announcement Date | 30/04/20 | 29/06/21 | 02/05/22 | 30/04/23 | 30/04/24 | 30/04/25 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.72x | 15.51x | 1.37% | 74.31B | |
| 29.59x | 8.5x | 26.48x | 0.04% | 56.95B | |
| 33.52x | 6.02x | 18.04x | 0.97% | 48.3B | |
| -21.51x | 223.61x | -23.09x | -.--% | 44.51B | |
| 34.27x | 3.31x | 14.29x | -.--% | 43.8B | |
| 47.24x | 5.47x | 29.99x | -.--% | 41.12B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 31.07B | |
| 33.5x | 7.16x | 18.6x | -.--% | 28.97B | |
| -15.28x | 5.82x | -7.31x | -.--% | 24.53B | |
| Average | 21.19x | 30.62x | 12.55x | 0.31% | 43.73B | |
| Weighted average by Cap. | 22.51x | 31.17x | 13.62x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALNEV Stock
- ALNEV Stock
- Valuation NEOVACS
Select your edition
All financial news and data tailored to specific country editions
